![Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c0b55551-f4ba-454f-8273-b6f14b234979/gr1_lrg.jpg)
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
![Identification and Quantification of Major Maillard Cross-links in Human Serum Albumin and Lens Protein - Journal of Biological Chemistry Identification and Quantification of Major Maillard Cross-links in Human Serum Albumin and Lens Protein - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3e95f130-41ff-46c2-b22a-4ac0d1db9990/gr1_lrg.jpg)
Identification and Quantification of Major Maillard Cross-links in Human Serum Albumin and Lens Protein - Journal of Biological Chemistry
![Prof. Dr. Michael Lederer - Prorektor Internationales und Weiterbildung - Hochschule Furtwangen | XING Prof. Dr. Michael Lederer - Prorektor Internationales und Weiterbildung - Hochschule Furtwangen | XING](https://profile-images.xing.com/images/658ade23b444a6ec76a6c4cedb26f086-2/michael-lederer.1024x1024.jpg)
Prof. Dr. Michael Lederer - Prorektor Internationales und Weiterbildung - Hochschule Furtwangen | XING
Neopentylesterderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel - European Patent Office - EP 033516
Dr. Maximilian Franke, CFA – Principal, Leader Capital Markets and Strategy Consulting Germany – Mercer Deutschland GmbH | LinkedIn
![Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/54b01b9b-5760-4eee-80a0-5cbc970cc1d7/gr3_lrg.jpg)